ASA. N. Slatetskaya

A. N. Slatetskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. N. Slatetskaya has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serological Profile of COVID-19 in Children with Comorbidities during Omicron Variant Circulation

    by M. S. Rajkovic, S. B. Chuelov, R. F. Sayfullin, Д. Д. Савельева, A. V. Belyakova, A. N. Slatetskaya, A. L. Rossina, M. A. Sayfullin, N. A. Mayanskiy, E. E. Petryaykina, et al.

    Тhe characteristics of the humoral immune response to SARS-CoV-2 in children, particularly those with comorbid conditions, remain incompletely understood. The observed variability in antibody production and the sensitivity of serological assays complicate the objective assessment of seroconversion in the pediatric population.Objective: To determine the qualitative and quantitative profiles of IgM and IgG antibodies against SARS-CoV-2 in children with somatic comorbidities during the acute phase of COVID-19 amid the circulation of the Omicron variant.Materials and Methods: A prospective, single-center, non-randomized cohort study was conducted involving hospitalized children with confirmed COVID-19 and underlying chronic conditions. Serological testing was performed on days 1, 8, and 14 of illness using enzyme-linked immunosorbent assay (ELISA) and immunochemiluminescence assay (ICLA) to measure IgM and IgG levels.Results: A total of 99 children with comorbidities were included in the analysis. The seropositivity rate for IgM remained low at all time points (up to 26.3% on day 14). IgG antibodies were detected in the majority of patients as early as day 1, with ELISA demonstrating higher sensitivity (77.6%) compared to ICLA (60%), peak IgG levels were observed on day 8, followed by a significant decline by day 14 (p < 0.01). Children with respiratory system diseases exhibited statistically higher IgG levels compared to those with hemoblastoses, solid tumors, primary immunodeficiencies, and nervous system disorders.Conclusions: Serological diagnosis of COVID-19 in children with comorbidities requires careful consideration of the testing method, disease timeline, and type of underlying somatic pathology. IgG antibodies serve as a more informative marker than IgM, with ELISA offering superior sensitivity.

  • Open Access

    COVID-19 in children with chronic digestive system pathology

    by M. S. Rajkovic, S. B. Chuelov, S. K. Pylaeva, Д. Д. Савельева, A. A. Chernysheva, A. L. Rossina, M. A. Sayfullin, A. N. Slatetskaya, E. G. Tsimbalova, E. E. Petryaykina, et al.

    COVID-19 in children is characterized by a predominance of mild and asymptomatic forms, along with frequent gastrointestinal symptoms. It is known that comorbid conditions are a risk factor for severe COVID-19 in children; however, the course of SARS-CoV-2 infection in children with chronic digestive system diseases remains under-researched. Objective. To identify the specific characteristics of COVID-19 in children with chronic digestive system diseases, assess risk factors for severe COVID-19, and evaluate the impact of immunosuppressive therapy on COVID-19 outcomes. Materials and Methods. A single-center cohort retrospective and prospective non-randomized study was conducted, including 74 patients with COVID-19 and chronic digestive system diseases and a control group of 30 patients with COVID-19 without comorbidities, all hospitalized in the infectious disease department of the Russian Children’s Clinical Hospital, Moscow, in 2022 and 2023. Results. Сhildren with underlying digestive system diseases were not at a higher risk of severe COVID-19 compared to the control group. Severe, uncontrolled somatic disease and the presence of two or more comorbidities were risk factors for complicated SARS-CoV-2 infection. The duration of detectable SARS-CoV-2 RNA in the study group was nine days. Conclusion. Patients with chronic digestive system diseases, including those receiving immunosuppressive therapy, do not appear to be at higher risk for severe or unfavorable COVID-19 outcomes; however, prolonged SARS-CoV-2 RNA shedding was observed. Risk factors for severe COVID-19 include the presence of two or more comorbidities and severe somatic disease.


  • Open Access

    COVID-19 in children with somatic pathology

    by M. S. Rajkovic, S. B. Chuelov, S. K. Pylaeva, Д. Д. Савельева, А. А. Chernysheva, S. A. Tosoeva, D. D. Namazova, J. N. Ivanova, A. N. Slatetskaya, A. L. Rossina, et al.

    The coronavirus infection is a pressing issue in modern healthcare, yet the characteristics of the SARS-CoV-2 infection course in children with comorbidities remain insufficiently studied. The aim of this study was to evaluate the clinical form, severity, and duration of SARS-CoV-2 virus shedding in pediatric patients with somatic diseases, depending on the comorbid pathology. Materials and Methods. A comprehensive single-center retrospective study was conducted, analyzing 314 medical records of patients hospitalized in the infectious diseases department of the Russian Children’s Clinical Hospital in Moscow over 11 months in 2022. The inclusion criterion was the presence of a laboratory-confirmed COVID-19 diagnosis. Results. Children with comorbidities were found to be predisposed to a more severe course of SARS-CoV-2 infection compared to the pediatric population in general. Children with hematological diseases were at the highest risk of adverse outcomes from COVID-19. Patients with oncological and hematological diseases and primary immunodeficiencies shed the SARS-CoV-2 virus significantly longer than patients with other somatic pathologies. The duration of SARS-CoV-2 RNA detection in patients with severe COVID-19 was significantly longer, which also correlated with the severity of the underlying somatic disease. Conclusion. Children with comorbidities are at risk for a more severe and prolonged course of SARS-CoV-2 infection.


  • Open Access

    Mucopolysaccharidosis I type: new management

    by S. V. Mikhaylova, A. N. Slateckay, E. A. Pristanskova, K. I. Kirgizov, O. V. Mendelevich, M. V. Zazhivikhina, V. P. Voroncova, E. Yu. Zakharova, E. A. Kamenec, E. Yu. Voskoboeva, et al.

    Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme. MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the gold standard for the treatment of MPS I-H in patients diagnosed and treated before 2–2.5 years of age, having a high rate of success. Enzyme replacement therapy (ERT) with human recombinant laronidase has also been demonstrated to be effective in ameliorating the clinical conditions of pre-transplant MPS I-H patients and in improving HSCT outcome, by peri-transplant co-administration. Nevertheless the long-term clinical outcome even after successful HSCT varies considerably, with a persisting residual disease burden. This review will focus on all these critical issues related to the management of MPS I-H.